Started: 9/2019
Study Name: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of xxx, a monoclonal antibody with an extended half-life against respiratory syncytial virus, in healthy late preterm and term infants (melody)
Indication: RSV
Principal Investigator: Steve Russell
COVID-19 and Flu Swab Test Study Contact our Research Coordinator to ask
Phase III Study of live-attenuated respiratory syncytial virus (RSV) vaccine in healthy
Measles, mumps, rubella, varicella vaccine compared with ProQuad, administered in healthy children
24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Health Infants Given 4 Doses at
